Alnylam Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '25 Dec 10, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Market Capitalization	54,230	30,350	24,021	29,238	20,282	15,100	Upgrade
Market Cap Growth	70.36%	26.35%	-17.84%	44.16%	34.32%	17.60%	Upgrade
Enterprise Value	54,279	30,296	24,278	29,564	19,873	14,639	Upgrade
Last Close Price	415.21	235.31	191.41	237.65	169.58	129.97	Upgrade
PS Ratio	16.84	13.50	13.14	28.18	24.02	30.64	Upgrade
PB Ratio	233.96	452.40	-108.87	-184.79	34.48	14.86	Upgrade
P/TBV Ratio	231.86	452.40	-	-	34.48	14.86	Upgrade
P/FCF Ratio	244.98	-	572.67	-	-	-	Upgrade
P/OCF Ratio	203.98	-	230.62	-	-	-	Upgrade
EV/Sales Ratio	16.91	13.48	13.28	28.50	23.54	29.70	Upgrade
EV/FCF Ratio	245.20	-	578.81	-	-	-	Upgrade
Debt / Equity Ratio	11.86	40.89	-12.16	-16.51	3.72	1.57	Upgrade
Debt / FCF Ratio	12.53	-	63.96	-	-	-	Upgrade
Asset Turnover	0.71	0.56	0.50	0.29	0.24	0.17	Upgrade
Inventory Turnover	6.83	3.86	2.85	1.57	1.74	1.19	Upgrade
Quick Ratio	2.37	2.61	2.86	3.17	3.79	4.23	Upgrade
Current Ratio	2.54	2.78	3.08	3.51	4.04	4.47	Upgrade
Return on Equity (ROE)	32.73%	-	-	-526.14%	-106.31%	-69.92%	Upgrade
Return on Assets (ROA)	3.65%	-2.74%	-4.78%	-13.65%	-12.56%	-17.85%	Upgrade
Return on Capital (ROIC)	5.74%	-4.19%	-7.17%	-18.77%	-16.46%	-23.80%	Upgrade
Return on Capital Employed (ROCE)	8.00%	-5.80%	-9.90%	-28.30%	-24.00%	-29.40%	Upgrade
Earnings Yield	0.08%	-0.92%	-1.83%	-3.87%	-4.21%	-5.68%	Upgrade
FCF Yield	0.41%	-0.14%	0.18%	-2.10%	-3.54%	-4.54%	Upgrade
Buyback Yield / Dilution	-4.82%	-2.20%	-2.64%	-2.73%	-3.01%	-5.24%	Upgrade

Updated Oct 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q